This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
This study demonstrates that the ablation of interaction of CD83 molecule between CCR7+DC and Tregs results in increased anti-tumor immune response, and identifies CD83 as a cellular and molecular checkpoint that restrains T cell responses and can be targeted therapeutically.
Ruparoshni Jayabalan, Ricardo Gonzalez-Delgado, Luis A. Castillo Montanez et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.